OPKO Health (NASDAQ:OPK) Upgraded to Sell by StockNews.com

StockNews.com upgraded shares of OPKO Health (NASDAQ:OPK) to a sell rating in a research report sent to investors on Friday morning.

OPK has been the topic of several other reports. Barrington Research restated an outperform rating and set a $1.50 price target on shares of OPKO Health in a report on Monday, April 1st. Piper Sandler restated an overweight rating and issued a $5.00 target price on shares of OPKO Health in a research note on Monday, April 1st. Finally, HC Wainwright reaffirmed a buy rating and issued a $3.00 price target on shares of OPKO Health in a report on Wednesday, May 8th.

OPKO Health Stock Performance

OPKO Health stock traded up $0.08 during mid-day trading on Friday, hitting $1.36. 2,345,016 shares of the company’s stock were exchanged, compared to its average volume of 3,370,309. The stock has a 50 day moving average of $1.23 and a two-hundred day moving average of $1.22. OPKO Health has a 1-year low of $0.85 and a 1-year high of $2.24. The company has a current ratio of 1.91, a quick ratio of 1.62 and a debt-to-equity ratio of 0.27.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.03). The company had revenue of $173.70 million during the quarter, compared to the consensus estimate of $182.99 million. OPKO Health had a negative return on equity of 17.89% and a negative net margin of 31.44%. The business’s revenue for the quarter was down 26.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.02) EPS. On average, equities analysts expect that OPKO Health will post -0.35 EPS for the current year.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 600,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was purchased at an average price of $0.93 per share, for a total transaction of $558,000.00. Following the completion of the acquisition, the chief executive officer now owns 209,468,225 shares of the company’s stock, valued at approximately $194,805,449.25. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders purchased 2,363,997 shares of company stock worth $2,271,556. Insiders own 47.26% of the company’s stock.

Institutional Trading of OPKO Health

Hedge funds have recently bought and sold shares of the company. IPG Investment Advisors LLC acquired a new position in OPKO Health during the 4th quarter valued at about $30,000. Virtu Financial LLC bought a new stake in shares of OPKO Health during the 1st quarter worth $26,000. River Wealth Advisors LLC acquired a new position in OPKO Health during the 3rd quarter valued at $38,000. SlateStone Wealth LLC acquired a new position in OPKO Health during the 1st quarter valued at $31,000. Finally, Northstar Group Inc. acquired a new position in shares of OPKO Health in the 4th quarter valued at $42,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.